Roivant’s Growth and Clinical Progress in Q1 2024
Roivant reports strong clinical progress, with significant Phase 3 study completions, revenue growth, and financial strength.
- Latest
- Trending
Roivant reports strong clinical progress, with significant Phase 3 study completions, revenue growth, and financial strength.
AbCellera Biologics Inc. progresses with their TCE platform and strategic partnerships, aiming for CTA submissions in Q2 2025.
Formation Bio secures $372M Series D led by Sanofi to enhance AI-driven drug development, focusing on workflow automation and AI ...
Medicxi launches Alys Pharmaceuticals with $100m funding to develop groundbreaking therapies in immunodermatology. The company aims to address unmet needs ...
Connect Biopharma has appointed James Zuie-chin Huang to its Board of Directors. Huang brings over 30 years of biotech experience ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.